Can be good (Skuchiyu monoantigen) strong straight scoliosis indications approved

BEIJING, April 28 (Reporter Li Yanan) Novartis Pharmaceuticals (China) announced on the 28th that can be good ting (Skuchiyu monoantigen) has been approved by china's State Drug Administration for the general treatment of poor efficacy of strong straight spinal itise adult patientsThis is the second indication approved in China after previously approved for the treatment of moderate lycopene psoriasis, and the first and only white interleukin inhibitor approved for the treatment of severe sylline synodsaccording to the introduction, strong scoliosis is a chronic inflammatory disease, belongs to rheumatism immunologyIn China, the prevalence of syllamal syllitis is about 0.3%, the age of onset is usually 13-31 years old, and is common in menData show that about 80% of patients with severe scoliosis have symptoms of spinal pain and fatigue, the proportion of morning stiffness up to 90%In addition, it can cause bone damagenormal conditions, the human spine is connected by flexible ligaments, so the back of the waist can move flexiblyThe connection point between the ligament and the upper and lower vertebrae is called the attachment point, while the attachment point of patients with strong scoliosis is repeated lyngngcing, producing a pathological new boneHealthy ligaments gradually begin to bone, resulting in bone clums, bone bridge, and eventually lead to spinal fusion and disability to varying degrees"As an inflammatory disease, it is important to suppress the level of inflammation and is the focus of clinical drug treatment at present," said DrHuang Qi, director of the rheumatology department at301 HospitalBut studies in recent years have found that even if inflammation levels are controlled, bone damage can worsenHow to double-pronged, especially 'inhibitthebone of bone structure progression' has become an urgent need to meet the treatment needsstrong straight syllade scoliosis from onset to final bone fusion, will go through several stages: osteoarthritis-fat deposition-bone-bridge-bone fusion"New bone formation" is the pathological basis for the progression of the entire course of the disease, while leukolysine-17A (IL-17A) is an important "boost" On the one hand, it is a key cytokine and inflammatory medium in the onset of adhesion, which can further promote the inflammatory cascade response, on the other hand, it is the key medium of bone remodeling, involving new bone formation Therefore, inhibition of IL-17A can block inflammatory pathways, relieve pain, and inhibit new bone formation to prevent further damage to bone structure , as the world's first and only all-human source IL-17A inhibitor, a number of clinical studies confirmed the multiple benefits of goodness: MEASURE2 studies showed that patients received 150 mg of good treatment for 4 weeks, back pain improved by 39% compared to baseline (placebo group: 15%), morning stiffness improved by 34.4% compared to baseline (placebo group: 14.8%), fatigue improved by 28% (placebo group): 8% Sustained treatment, 97% of baseline boneless patients and 73% of baseline boneless patients withno new bone growth within 2 years, nearly 80% of patients with spinal injuries did not worsen within 4 years IL-17A is located downstream of the entire inflammatory pathway, and the whole-human preparation process reduces the risk of adverse reactions Studies have shown that there have been no reports of increased susceptibility to TB in patients treated with good treatment, and no reports of reactivation of hepatitis B have been reported with good treatment, and the incidence of anti-drug antibodies in 5 years is 1% as the head of clinical research in Phase III of Skuchiyu Mono-Anti-China, Professor Huang Qi said: "The emergence of Scuchiyu mono-resistance has undoubtedly provided patients with a new treatment option and hope, but also let us on the IL-17A this new target in the field of strong scoliosis clinical performance and potential is full of expectations." We want to see more Chinese patients benefit from a new generation of innovative drugs is known to be listed in many countries and regions, including the European Union and the United States, approved for the treatment of psoriasis, psoriasis arthritis and stoic osteorapitis Source: China News Network